Our analysis identified the prognostic gene signature of CD4/CD68/CSF1R, and revealed the intrinsic relevance of these molecular alterations and immune features in predicting clinical outcomes and chemotherapy responses in patients with OSA. The gene discussed is CD68; the disease is obstructive sleep apnea syndrome.